Summit is frank about plans for the laser vision correction company while rival VISX plays card closer to chest
This article was originally published in Clinica
Summit Technology's CEO Robert Palmisano recalls that when he joined the troubled laser vision correction company last year he did not expect a bed of roses. "And obviously I haven't found one," he told investors attending the Hambrecht & Quist Healthcare Conference this month in San Francisco.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.